Table 1.
Response to Treatment
| Patient no. (treated on study) | Best Response | Duration of Response (months) | Ruxolitinib Discontinued | Last Known Vital Status | Adverse Events (Grade ≥2)** |
|---|---|---|---|---|---|
| 1* | CR | 3.5 | Yes (due to recurrence) | Alive, without HLH | Febrile neutropenia (Grade 4) |
| 2* | CR | 23.5+ | Yes (due to toxicity) | Alive, without HLH | Pain in extremity (Grade 2) |
| 3* | CR | 35.5+ | No | Alive, without HLH | Pneumonitis (Grade 2); Fatigue (Grade 3) |
| 4* | CR | 17+ | Yes (treatment no longer required) | Alive, without HLH | Nausea (Grade 2) |
| 5* | CR | 17.5+ | Yes (treatment no longer required) | Alive, without HLH | None |
| 6 | PR | 12+ | No | Alive, without HLH | None |
| Patient no. (treated off study) | |||||
| 7* | PR | 41.5+ | No | Alive, without HLH | - |
| 8* | PR | 34.5+ | Yes (treatment no longer required) | Alive, without HLH | Headache (Grade 2) |
| 9 | PR | 16.5+ | Yes (treatment no longer required) | Alive, without HLH | - |
| 10 | NR | N/A | N/A | Died, with HLH (and disseminated candidiasis) | - |
| 11 | PR | 1.5 | Yes (due to recurrence) | Alive, without HLH | - |
| 12 | NR | N/A | N/A | Died, with HLH (and septic shock, VRE bacteremia, neutropenic colitis) | - |
| 13 | NR | N/A | N/A | Died, with HLH (and invasive sinus and pulmonary aspergillosis complicated by hemorrhagic and septic shock) | - |
*
Previously reported (3).
**
Unlikely, possibly, or probably related to ruxolitinib.
+
response ongoing at time of last follow-up
Abbreviations: complete response (CR), partial response (PR), no response (NR), not applicable (N/A)